Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
0.5589
-0.0067 (-1.18%)
Feb 24, 2026, 10:32 AM EST - Market open
Longeveron Employees
Longeveron had 25 employees as of December 31, 2024. The number of employees increased by 1 or 4.17% compared to the previous year.
Employees
25
Change (1Y)
1
Growth (1Y)
4.17%
Revenue / Employee
$57,480
Profits / Employee
-$853,640
Market Cap
11.92M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 25 | 1 | 4.17% | 25 | 0 |
| Dec 31, 2023 | 24 | 3 | 14.29% | 23 | 1 |
| Dec 31, 2022 | 21 | 1 | 5.00% | 19 | 2 |
| Dec 31, 2021 | 20 | 8 | 66.67% | 18 | 2 |
| Dec 31, 2020 | 12 | -4 | -25.00% | 12 | 0 |
| Sep 30, 2020 | 12 | -4 | -25.00% | 12 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| CytoMed Therapeutics | 43 |
| Lunai Bioworks | 29 |
| BioLineRx | 28 |
| BioCardia | 20 |
| Moleculin Biotech | 17 |
| NewcelX | 15 |
| Traws Pharma | 7 |
LGVN News
- 10 days ago - Longeveron® Appoints Stephen H. Willard as Chief Executive Officer - GlobeNewsWire
- 19 days ago - Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program - GlobeNewsWire
- 26 days ago - Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) - GlobeNewsWire
- 2 months ago - Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 - GlobeNewsWire
- 3 months ago - Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging - GlobeNewsWire
- 3 months ago - Longeveron New MRI Biomarker Data Linking Neuroinflammation to Clinical Outcomes in Patients with Mild Alzheimer's Disease Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) - GlobeNewsWire
- 3 months ago - Longeveron Laromestrocel Data in Alzheimer's Disease Selected for Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD 2025) - GlobeNewsWire
- 3 months ago - Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy - GlobeNewsWire